How did the original COVID-19 vaccine hold up? A massive study tested its safety and effectiveness in nearly 47,000 people.

This was a massive, multi-stage effort to find a safe and effective COVID-19 vaccine. The study tested three different RNA vaccine candidates in nearly 47,000 healthy people. The goal was to pick the best formula and the right dose. The research unfolded in phases. First, scientists worked to identify the preferred vaccine candidate and dose. Then, they expanded the study to test how well that chosen vaccine actually worked at preventing COVID-19. The candidate selected for this large-scale efficacy test was called BNT162b2, given as two shots, 21 days apart. The study included people from age 12 up to 85, looking at how the vaccine performed in different age groups. A key part of the research was understanding 'boostability'—whether giving an extra dose months later could strengthen protection, especially against new variants of the virus. To test this, some participants received a third dose of the original vaccine or a version tweaked to target a specific variant. The study also enrolled a new group of people who had never had COVID-19 or a vaccine to test a two-dose series of that variant-targeted shot. Throughout, the study closely tracked local reactions (like pain at the injection site) and systemic events (like fever) after each dose to build a clear picture of safety.